Evidence map›Paper›PMID 35702891›Full record

ArticleCancer research2022

PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth.

Sally E Claridge, Benjamin D Hopkins

Open access · bronzeAbstract readEditorialComment
In one paragraph

Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sally E ClaridgeDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-2539-0178
Benjamin D HopkinsDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Icahn School of Medicine at Mount Sinai · US

Funding

TRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6M
Utilizing Precision Medicine to elucidate the mechanisms underpinning treatment efficacyR00CA230384 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOPKINS, BENJAMIN D. · 2019 to 2021
$718k
Utilizing Precision Medicine to elucidate the mechanisms underpinning treatment efficacyK99CA230384 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI HOPKINS, BENJAMIN D. · 2018 to 2018
$108k
NCI NIH HHS K99 CA230384NCI NIH HHS R00 CA230384NCI NIH HHS T32 CA078207
6 · The paper itself

Abstract

PI3K signaling plays an integral role in cells, coordinating the necessary alterations in cellular metabolism and programs to support survival and proliferation. In the first genome-wide analysis of alternative splicing in PIK3CA-mutant breast cancer, Ladewig and colleagues show that activating mutations in PIK3CA alter the use of known exons and splice junctions, leading to changes in gene expression and transcription factor activity that promote an oncogenic phenotype. Their work reveals a novel mechanism underlying the functional impact of PI3K signal activation in the context of breast cancer, where PIK3CA mutations are common and PI3K inhibitors are part of the standard of care. Their studies uncover a feedforward mechanism by which PI3K signaling enables a shift in the spectrum of translated splice variants as another method through which the PI3K pathway has evolved to regulate its own activity, thereby modifying the cellular response to upstream activation based on the signaling that has come before. These findings have profound implications for understanding the evolution of the PI3K pathway and the rewiring of cells in response to prolonged or repeated signal activation. See related article by Ladewig et al., p. 2269.

Indexed as

Breast NeoplasmsPhosphatidylinositol 3-KinasesCell Line, TumorClass I Phosphatidylinositol 3-KinasesFemaleHumansMutationRNA SplicingTranscriptomeClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-Kinases

Identifiers

PMID35702891
PMCPMC10309115
OpenAlexW4282964441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.